Navigation Links
Dragon retains leading investor relations firm
Date:3/17/2008

VANCOUVER, March 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company, today announced it has retained cQuest, a capital markets advisory affiliate of Christensen, to facilitate and execute its investor and media relations campaigns. cQuest specializes in assisting companies with market capitalizations of less than $200 million to achieve fair market valuation and strengthen brand recognition in the global financial markets and financial media. Retaining cQuest reinforces Dragon's commitment to maximizing shareholder value by improving external communications and increasing visibility within the financial community.

"We are very excited to be working with cQuest," said Ms. Maggie Deng, Dragon's Chief Operating Officer. "The Dragon management team is committed to creating value for our shareholders with best-in-class communications and has placed a great deal of effort in finding the right investor relations firm to accomplish this goal. With its extensive global investor relations expertise with small and micro-cap companies and depth of pharmaceutical industry experience, we are confident that cQuest will assist in positioning Dragon Pharmaceutical within the investor community with a more comprehensive and customized investor and media relations program, a critical step to achieving our long term goals."

About Dragon Pharmaceutical Inc.

--------------------------------

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including 7-ACA, a key intermediate to produce cephalosporin antibiotics, Clavulanic Acid, and formulated cephalosporin antibiotic drugs. Dragon is the third largest 7-ACA producer and the first manufacturer and market leader of Clavulanic Acid products in China. Dragon utilizes its nationwide sales distribution network, close customer relationships, understanding of local markets and customer needs and low cost structure to outperform its international and domestic peers. With an annual capacity of 780 tons, Dragon is the largest exporter of 7-ACA in China. To learn more about Dragon Pharmaceutical Inc., please visit http://www.dragonpharma.com.

About cQuest

------------

cQuest is an affiliate of Christensen, a leading global capital markets advisory firm with offices in New York, Hong Kong, Phoenix, Montreal and Calgary. Providing its clients with a customized choice of investor relations and financial communication solutions, designed to fit clients' individual needs, cQuest assists companies with market capitalizations of less than $200 million achieve fair market valuation and strengthened brand recognition in the global financial markets.

More information can be found at http://www.christensenir.com.

This press release contains forward looking statements, including but not limited to, that the Company will continue to experience growth in sales of its main products, that it will continue to be able to improve its production technology and efficiency, that it will continue to achieve continuous growth in business and profitability in the near future. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the views of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports filed with the Securities and Exchange Commission.

CONTACT: Dragon Pharmaceutical Inc., Maggie Deng, Chief Operating Officer, Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784, Email: irdragon@dragonpharma.com, Website: http://www.dragonpharma.com


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
2. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
3. Dragon Announces R&D Achievement in Biotech Manufacturing Process
4. Dragon announces new product launch; increase in annual production output capacity
5. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
10. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
11. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):